Here's a look at some of the top regulatory stories for medical device companies this week: Recent progress on demographic information and clinical trials; Moving toward a national medical device postmarket surveillance system; Medtronic wins CE Mark for Euphora Semicompliant balloon catheter; Simplify Medical wins CE Mark for MRI-safe cervical disc
Medtronic has snatched up Advanced Uro-solutions, a Tennessee company with an FDA-cleared neurostimulation device to treat overactive bladder.
Medtronic (NYSE:MDT) has wrapped up yet another acquisition, buying Advanced Uro-Solutions, a Tennessee company whose neurostimulation products focus on treating patients with overactive bladder, for an undisclosed amount of money.
Medtronic’s DBS therapy for treatment-resistant epilepsy has produced long-lasting improvements in quality of life after 5 years, according to detailed results from a pivotal clinical trial.
Medicare plans to provide supplemental reimbursement to hospitals for patients treated on an outpatient basis with Medtronic's new In.Pact Admiral drug-coated balloon for peripheral artery disease (PAD) in the upper leg.
Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.
Medtronic will work with the American Heart Association/American Stroke Association to reduce repeat strokes for which a cause isn’t known.
Medtronic (NYSE:MDT) and the American Heart Association/American Stroke Association will ally on a project focused on reducing repeat strokes for which a cause isn’t known.
Medtronic CEO Omar Ishrak tells analysts the company's managed services business for cath labs is expanding into new markets, with booked sales topping the $1 billion mark through its fiscal 3rd quarter.